Back
Compare AU
Compare FEMX vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Fidelity Global Emerging Markets Active ETF (FEMX) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
FEMX | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 117 | 65 |
Median incremental investment | $1,001.41 | $865.32 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,570.04 | $1,950.63 |
Average age group | > 35 | 26 - 35 |
Key Summary
FEMX | DRUG | |
|---|---|---|
Strategy | FEMX.AX was created on 2013-12-16 by Fidelity. The fund's investment portfolio concentrates primarily on total market equity. To achieve returns in excess of the MSCI Emerging Markets Index NR over the suggested minimum investment time period of seven years plus. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Taiwan Semiconductor Manufacturing Co Ltd (6.97 %) HDFC Bank Ltd (6.08 %) Naspers Ltd Class N (4.57 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Financials (37.48 %) Information Technology (17.04 %) Consumer Discretionary (11.16 %) | Other (76.26 %) Communication Services (33.53 %) Health Care (23.55 %) |
Top 3 countries | India (24.10 %) China (17.96 %) Taiwan (13.38 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.99 % | 0.57 % |
Key Summary
FEMX | DRUG | |
|---|---|---|
Issuer | Fidelity | BetaShares |
Tracking index | MSCI EM (Emerging Markets) | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.99 % | 0.57 % |
Price | $6.49 | $7.59 |
Size | $183.703 million | $173.344 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.28 % | 1.89 % |
Market | ASX | ASX |
First listed date | 05/11/2018 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
FEMX | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 117 | 65 |
Median incremental investment | $1,001.41 | $865.32 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,570.04 | $1,950.63 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
FEMX | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
FEMX | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |